Loading...
XSHE
000952
Market cap277mUSD
Jul 10, Last price  
5.64CNY
1D
3.87%
1Q
-19.54%
Jan 2017
-64.59%
Name

Hubei Guangji Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:000952 chart
P/E
—
P/S
3.13
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.50%
Rev. gr., 5y
-4.50%
Revenues
624m
-2.32%
571,782,750448,197,426483,316,187453,316,737394,156,326487,080,365485,858,037560,355,471714,723,952801,556,324843,830,941731,340,516688,169,322837,106,649785,573,170797,642,746797,642,745737,819,478638,801,582623,974,702
Net income
-404m
L+36.98%
89,097,44543,003,75313,979,6024,845,510-95,564,0732,421,982-218,730,74120,921,473141,839,237105,211,601171,728,91786,943,19574,647,107110,107,173110,107,17650,333,65450,333,658-140,248,067-295,291,149-404,494,390
CFO
60m
+9,120.62%
125,954,626331,975,678220,700,152077,177,84081,878,424108,020,36495,158,31400167,074,831178,828,210231,438,796144,200,478119,381,52575,907,30345,079,614-148,963,590655,35760,427,978
Dividend
May 27, 20220.06 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hubei Guangji Pharmaceutical Co., Ltd. engages in the production and operation of pharmaceutical raw materials, pharmaceutical preparations, and feed additives. It specializes in production of vitamin B2, B6 and pharmaceutical products. Vitamin B2, is also known as riboflavin. it is used in medicine APIs (Active Pharmaceutical Ingredient), feed additives, and food additives. Its products are divided into raw material series products and preparation series products. The series of raw materials are pharmaceutical grade, food grade, 98% feed grade, 80% feed grade nuclear yellow and riboflavin sodium phosphate. The preparation series products are oral solid preparations and large infusions. The company was founded on May 28, 1993 and is headquartered in Wuxue, China.
URL
https://www.guangjipharm.com/
IPO date
Nov 12, 1999
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT